Roche Signs Machine-Learning Neuroscience Deal With Recursion

Roche Holding AG sealed a decade-long collaboration deal with U.S. biotech Recursion Pharmaceuticals Inc. to use machine learning to search out potential drugs for neuroscience and cancer.

The deal allows for as many as 40 experimental programs to emerge from the Recursion technology, part of a broader Roche effort to invest in platforms that can underpin an array of medicines, said James Sabry, Roche’s head of partnering. The Swiss drugs giant will pay Recursion $150 million upfront, plus royalties and development, commercialization and revenue milestones that could exceed $300 million for each project.